Journal article
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 89.5KB, Terms of use)
-
(Preview, Accepted manuscript, pdf, 398.2KB, Terms of use)
-
(Preview, Accepted manuscript, pdf, 563.4KB, Terms of use)
-
- Publisher copy:
- 10.1136/annrheumdis-2019-215183
Authors
- Publisher:
- BMJ Publishing Group
- Journal:
- Annals of the Rheumatic Diseases More from this journal
- Volume:
- 78
- Issue:
- 10
- Pages:
- 1439-1441
- Publication date:
- 2019-04-24
- Acceptance date:
- 2019-04-11
- DOI:
- ISSN:
-
1468-2060
- Keywords:
- Pubs id:
-
pubs:987916
- UUID:
-
uuid:249fefcd-2997-4c34-9b50-d34d93b1533e
- Local pid:
-
pubs:987916
- Source identifiers:
-
987916
- Deposit date:
-
2019-04-12
Terms of use
- Copyright holder:
- Sweet et al
- Copyright date:
- 2019
- Notes:
- © Author(s) (or their employer(s)) 2019. This is the Accepted Manuscript version of the article. The final version is available online from BMJ Publishing Group at: 10.1136/annrheumdis-2019-215183
If you are the owner of this record, you can report an update to it here: Report update to this record